Earnings Call Summary | InspireMD(NSPR.US) Q1 2024 Earnings Conference
Earnings Call Summary | InspireMD(NSPR.US) Q1 2024 Earnings Conference
The following is a summary of the InspireMD Inc. (NSPR) Q1 2024 Earnings Call Transcript:
以下是InspireMD Inc.（NSPR）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
InspireMD reported a Q1 2024 total revenue of $1.5 million, marking an increase of approximately 22% from the previous year.
The company sold a total of 2,553 CGuard stents in Q1 2024, a 25.6% increase from Q1 2023.
Gross profit for Q1 2024 was $292,000, down by 21.6% due to an increase in training costs.
There was a significant increase in Q1 2024 operating expenses, which rose by 62.1% to $7.7 million, driven largely by higher share-based compensation.
A net loss of $7.32 million or $0.21 per share was reported for Q1 2024.
InspireMD報告稱，2024年第一季度的總收入爲150萬美元，比上年增長了約22％。
該公司在 2024 年第一季度共售出 2,553 個 cGuard 支架，比 2023 年第一季度增長了 25.6%。
由於培訓成本的增加，2024年第一季度的毛利爲29.2萬美元，下降了21.6％。
2024年第一季度的運營支出大幅增加，增長了62.1％，達到770萬美元，這主要是由於股票薪酬的增加。
2024年第一季度報告的淨虧損爲732萬美元，合每股虧損0.21美元。
Business Progress:
業務進展：
The C-Guardians trial continues, with expected results to be presented at the Leipzig Interventional Course in 2024.
The company aims to submit a premarket approval application later this year and is targeting a US commercial launch in early 2025.
InspireMD has entered a strategic agreement with the Jacobs Institute to conduct a feasibility study of CGuard Prime.
The FDA-approved study is set to enroll its first participant in Q2 2024.
Looking ahead, the company plans to study and submit its SwitchGuard system and C-Guard TCAR stent platform for clearance in 2026.
C-Guardians試驗仍在繼續，預計結果將在2024年的萊比錫介入課程上公佈。
該公司的目標是在今年晚些時候提交上市前批准申請，並計劃在2025年初在美國商業上市。
InspireMD已與雅各布斯研究所簽訂戰略協議，對cGuard Prime進行可行性研究。
這項經美國食品藥品管理局批准的研究將在2024年第二季度招收其第一位參與者。
展望未來，該公司計劃在2026年研究並提交其SwitchGuard系統和C-Guard TCAR支架平台以供審批。
More details: InspireMD IR
更多詳情： InspireMD IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。